You are here: Home / Biomarkers / Mitochondrial Genome Deletion for Detection of Prostate Cancer

Mitochondrial Genome Deletion for Detection of Prostate Cancer

Basics

Aliases:
This biomarker is also known as:
  • Mitochondrial deletion for detection of prostate cancer,
  • Prostate Core Mitomic Test™,

Description…

The Prostate Core Mitomic Test™ is based upon a 3.4 kb mitochondrial genome deletion (3.4 mtdelta) that was identified through PCR analysis of frozen prostate cancer samples. In cancer research it has been found that deletions in mitochondrial DNA can correlate with cellular changes that indicate development of cancer. This deletion includes the terminal 22 bases of MT-ND4L, all of MT-ND4, 3 tRNAs (histidine, serine 2, and leucine 2), and all except the terminal 24 bases of MT-ND5.

Attributes

QA State: Curated
Type: Genomic
Short Name:
HGNC Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Three
QA State: Curated

Overview

Mitochondrial DNA deletions are known to be associated with many cancers. This 3.4 kb deletion was found to be specific to prostate cancer.

Performance Comment

Both pilot and confirmation studies demonstrated that this 3.4 kb mitochondrial deletion is a highly significant biomarker for prostate cancer. In the pilot study the difference between benign and malignant core biopsy samples was P > .0001. Results from the larger study were identical. In a blinded external validation study, sensitivity was 83% and specificity was 79%. The area under the ROC curve was 0.87 for the deletion.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Biomuta

No associated Biomuta entries found.